Seven Qiming Venture Partners Portfolio Companies Named to Cyzone 100 Future Unicorns List
Uncovering the Forces of Business Transformation Over the Next 3–5 Years
Recently, the 2025 Cyzone 100 Future Unicorn rankings were officially announced. Now in its 16th year, this list remains dedicated to identifying "the forces shaping commercial transformation over the next 3–5 years." Seven Qiming Venture Partners portfolio companies were named to the 2025 Cyzone 100 Future Unicorn list.
Future Intelligent, Minghui Medical, Kangrun Biotech, Pulnovo Medical
Shengshu Technology, Wushuang Medical, Xinchuangyuan
were honored as
2025 Cyzone 100 Future Unicorns
Selection Criteria
This year's evaluation drew from more than 300 applicant companies. Centered on long-term growth logic, the selection process assessed five dimensions — founding team, technological moat, commercialization capability, capital appeal, and growth momentum — through multiple rounds of research and review, ultimately identifying 100 companies with the greatest potential to make the leap to unicorn status.
Cyzone noted that the 2025 rankings reveal an accelerating convergence of new technology and capital cycles: AI companies surged 52% year-over-year, with Beijing leading at 38 entries; listed companies averaged a valuation of 2.57 billion RMB; 61% had completed five or more funding rounds; and 70% had already established global operations spanning core markets in Europe and North America.
Source | Cyzone
Past Coverage
Qiming Weekly · Portfolio News in Brief, Vol. 02, Jan. 20, 2026 Qiming Honors | 5 Qiming Venture Partners Investors Named to ChinaVenture 2025 Annual Investors Rankings Qiming Honors | 5 Qiming Venture Partners Investors Named to Forbes China 2025 Midas List
Founded in 2006, Qiming Venture Partners currently manages 11 USD funds and 7 RMB funds, with total assets under management reaching $9.5 billion. Since its inception, the firm has focused on investing in outstanding early- and growth-stage companies in Technology and Healthcare.
To date, Qiming Venture Partners has invested in over 580 high-growth innovative companies, of which more than 210 have gone public on the New York Stock Exchange, NASDAQ, Hong Kong Exchanges and Clearing Limited, Shanghai Stock Exchange, and Shenzhen Stock Exchange, or exited through M&A and other means. More than 80 portfolio companies have become recognized unicorns or super-unicorns.
Many Qiming Venture Partners portfolio companies have grown into the most influential players in their respective fields, including Xiaomi (01810.HK), Meituan (03690.HK), Bilibili (NASDAQ:BILI, 09626.HK), Zhihu (NYSE:ZH, 02390.HK), Roborock (688169.SH), Hesai Technology (NASDAQ:HSAI, 02525.HK), UBTECH (09880.HK), WeRide (NASDAQ:WRD, 00800.HK), HyperStrong (688411.SH), Insta360 (688775.SH), Unisound (09678.HK), Biren Technology (06082.HK), Zhipu AI (02513.HK), Gan & Lee Pharmaceuticals (603087.SH), Tigermed (300347.SZ, 03347.HK), Zai Lab (NASDAQ:ZLAB, 09688.HK), CanSino Biologics (688185.SH, 06185.HK), Schrödinger (NASDAQ:SDGR), MicroPort EP MedTech (688617.SH), Sanyou Medical (688085.SH), Amoy Diagnostics (300685.SZ), SinoCellTech (688520.SH), Insilico Medicine (03696.HK), Hohobio, Yuanxin Technology, MediLink Therapeutics, LaNova Medicines, StepFun, and others.